New drug JUV-161 takes first step in human safety trial
Knowledge-focused
Ongoing
This early-stage study tests JUV-161 for the first time in people. It aims to check safety and how the drug moves through the body in 72 healthy adults aged 18 to 60. Results will help plan future studies in patients with muscle diseases like myotonic dystrophy.
Phase: PHASE1 • Sponsor: Juvena Therapeutics • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC